Last reviewed · How we verify

NCT04193163: ESOP2

Observational Study Conducted on Patients Receiving the ESOP 2 Stem to Confirm Security and Performance of the Device

Terminated Last updated 2 February 2026
What this trial tests

trial testing Hip prosthesis - ESOP 2 cementless femoral stem in Hip Disease in 10 participants. Terminated before completion.

Timeline
1 December 2019
Primary endpoint
1 September 2022
1 September 2022

Quick facts

Lead sponsorFH ORTHO
StatusTerminated
Study typeOBSERVATIONAL
Enrollment10
Start date1 December 2019
Primary completion1 September 2022
Estimated completion1 September 2022
Sites7 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

FH ORTHO

Who can join

18 and older, any sex, with Hip Disease or Hip Fractures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a post-market clinical follow-up conducted in order to collect long-term data on security and performance of the ESOP 2 stem, which is intended to be implanted in case of total hip replacement, when used in real life conditions according to the instructions for use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hip Disease

Currently open trials in the same condition.

Other FH ORTHO trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04193163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing